Skip to the answer

Paclitaxel Uses, Dosage, Side Effects and Interactions

Brand names
Abraxane

Abraxane was approved by the FDA in January 2005 as an injection. An FDA-approved generic with the same active ingredient is listed.

Paclitaxel Protein Bound Particles Albumin Bound

Paclitaxel Protein Bound Particles Albumin Bound is a brand of paclitaxel that comes as an injection. An FDA-approved generic with the same active ingredient is listed.

Paclitaxel is a chemotherapy medicine used intravenously to treat certain breast, lung, ovarian, and pancreatic cancers, as well as AIDS-related Kaposi's sarcoma.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About PaclitaxelType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Paclitaxel in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Paclitaxel is a chemotherapy given into a vein for breast, ovarian, non-small cell lung and pancreatic cancers and AIDS-related Kaposi's sarcoma, and it jams the internal scaffolding (microtubules) cancer cells need to divide; it has been a cornerstone of cancer treatment since about 1992, with FDA-approved generic versions listed. It is a demanding treatment, and the effects most people notice are hair loss, tiredness, aching joints and muscles, and numbness or tingling in the hands and feet. Its boxed warning is a severe drop in infection-fighting white blood cells (neutropenia), so blood counts are checked often, and any fever or chills means calling your care team right away.

Key Takeaways From the HelloPharmacist Team

  • Expect each dose as an infusion into a vein at a clinic, lasting a few hours and most often given every 3 weeks.
  • Tell your team early about numbness, tingling or weakness in your hands or feet, because worsening nerve damage may mean adjusting the dose.
  • Standard paclitaxel, unlike albumin-bound Abraxane, comes with a steroid, antihistamine and acid reducer first; report breathing trouble or hives during infusion immediately.
  • List every medicine for your team, since clarithromycin, ketoconazole, itraconazole, rifampin, carbamazepine and gemfibrozil can raise or lower paclitaxel levels.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Paclitaxel.

Paclitaxel must be given under the supervision of a doctor experienced in cancer chemotherapy, and only where emergency treatment is immediately available. Severe allergic reactions — including life-threatening drops in blood pressure, difficulty breathing, swelling, and hives — have occurred in 2–4% of patients, and some have been fatal even in patients who received pre-medications. If you have a severe reaction, you must not receive paclitaxel again. Paclitaxel also causes significant drops in white blood cells (neutropenia), which can lead to serious infections. It should not be given if your neutrophil (infection-fighting white blood cell) count is too low at the start of treatment. Regular blood tests are required throughout treatment to monitor for this.

Read the full warning on DailyMed →

Paclitaxel by the Numbers

Strengths
3
in one form
Makers and packagers
20
Earliest FDA record
1992
Rank by Medicaid prescriptions
#618 of 1,682 drugs
More prescriptions than 63% of the 1,682 drugs we measure
58,387 prescriptions, Q1–Q4 2025

Patient Information Guide for Paclitaxel

What It’s Used For

Paclitaxel is a chemotherapy medicine given intravenously to treat several types of cancer. Specific approvals depend on the product formulation:

  • Abraxane and albumin-bound paclitaxel products: Metastatic breast cancer after combination chemotherapy has failed; locally advanced or metastatic non-small cell lung cancer (first-line, with carboplatin); metastatic adenocarcinoma of the pancreas (first-line, with gemcitabine)
  • Paclitaxel injection (solution/concentrate): Advanced ovarian cancer (as subsequent therapy, or first-line with cisplatin); breast cancer after chemotherapy failure; adjuvant treatment of node-positive breast cancer (given sequentially with standard chemotherapy); first-line non-small cell lung cancer in combination with cisplatin; second-line AIDS-related Kaposi's sarcoma

How It Works

Paclitaxel is a microtubule inhibitor. Microtubules are tiny structural rods inside cells that cells use to pull their chromosomes apart when dividing. Paclitaxel locks these rods in place, preventing the normal reorganization that must happen for a cell to divide. With the division machinery jammed, cancer cells cannot multiply and instead die off. It disrupts this process both during cell division (mitosis) and during the day-to-day life of the cell.

Drug Class

Drug Class

  • Microtubule Inhibitor
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • Microtubule Inhibitor

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)

None listed for Paclitaxel in the FDA’s index.

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)
  • Microtubule Inhibition

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Paclitaxel in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Taxanes

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Paclitaxel is always given as an intravenous (IV) infusion in a clinic or hospital — never taken by mouth. The schedule varies by product and the condition being treated: it may be administered once every three weeks or on specific days within a multi-week cycle.

Your oncologist will determine your schedule based on which product you are receiving and what you are being treated for.

  • Before each infusion of standard paclitaxel injection, pre-medications are required to reduce the risk of serious allergic reactions
  • Albumin-bound formulations such as Abraxane must not be substituted for other paclitaxel products — they are different and not interchangeable
  • Always follow your prescriber's and infusion team's instructions exactly; do not adjust your schedule without talking to your doctor

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Paclitaxel 6 mg/mL Injection

Ovarian cancer
Adults not treated before · 175 mg/m2 Usual dose 175 mg/m2 every 3 weeks
  • Paclitaxel injection 175 mg/m2 intravenously over 3 hours followed by cisplatin 75 mg/m2, every 3 weeks
Adults not treated before · 135 mg/m2 Usual dose 135 mg/m2 every 3 weeks
  • Paclitaxel injection 135 mg/m2 intravenously over 24 hours followed by cisplatin 75 mg/m2, every 3 weeks
Adults treated with chemotherapy before Dose 135 mg/m2 or 175 mg/m2
  • 135 mg/m2 or 175 mg/m2 intravenously over 3 hours every 3 weeks
Breast cancer
Adults with node-positive breast cancer, after surgery Usual dose 175 mg/m2 every 3 weeks
  • 175 mg/m2 intravenously over 3 hours every 3 weeks for 4 courses, sequentially after doxorubicin-containing combination chemotherapy
Adults whose cancer spread or returned after earlier chemotherapy Usual dose 175 mg/m2 every 3 weeks
  • 175 mg/m2 intravenously over 3 hours every 3 weeks
Non-small cell lung cancer
For adults
Usual dose 135 mg/m2 every 3 weeks
  • 135 mg/m2 intravenously over 24 hours followed by cisplatin 75 mg/m2, every 3 weeks
24 hour infusion: transaminase < 2 × ULN and bilirubin ≤ 1.5 mg/dL
For adults
Starting dose 135 mg/m2

Good to know

First course; reduce further based on tolerance

ULN means upper limit of normal, the top of the normal range for the test.

24 hour infusion: transaminase 2 to < 10 × ULN and bilirubin ≤ 1.5 mg/dL
For adults
Starting dose 100 mg/m2

Good to know

First course; reduce further based on tolerance

ULN means upper limit of normal, the top of the normal range for the test.

24 hour infusion: transaminase < 10 × ULN and bilirubin 1.6 to 7.5 mg/dL
For adults
Starting dose 50 mg/m2

Good to know

First course; reduce further based on tolerance

ULN means upper limit of normal, the top of the normal range for the test.

24 hour infusion: transaminase ≥ 10 × ULN or bilirubin > 7.5 mg/dL
For adults
Not recommended

ULN means upper limit of normal, the top of the normal range for the test.

3 hour infusion: transaminase < 10 × ULN and bilirubin ≤ 1.25 × ULN
For adults
Starting dose 175 mg/m2

Good to know

First course; reduce further based on tolerance

ULN means upper limit of normal, the top of the normal range for the test.

3 hour infusion: transaminase < 10 × ULN and bilirubin 1.26 to 2 × ULN
For adults
Starting dose 135 mg/m2

Good to know

First course; reduce further based on tolerance

ULN means upper limit of normal, the top of the normal range for the test.

See the Full Dosing Instructions on DailyMed →

Paclitaxel 100 Mg/20 mL and 100 Mg/100 Mg Injection

Breast cancer that has spread
Adults Usual dose 260 mg/m2 every 3 weeks
  • 260 mg/m2 intravenously over 30 minutes every 3 weeks
Adults with moderate liver problems Starting dose 200 mg/m2

Good to know

First course; consider increase to 260 mg/m2 if tolerated for two cycles

Adults with severe liver problems Starting dose 200 mg/m2

Good to know

First course; consider increase to 260 mg/m2 if tolerated for two cycles

Non-small cell lung cancer
Adults Usual dose 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle
  • 100 mg/m2 intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle
  • Carboplatin on Day 1 of each cycle immediately after
Adults with moderate liver problems Starting dose 80 mg/m2

Good to know

First course; consider increase to 100 mg/m2 if tolerated for two cycles

Pancreatic cancer that has spread
For adults
Usual dose 125 mg/m2 on Days 1, 8, and 15 of each 28-day cycle
  • 125 mg/m2 intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
  • Gemcitabine immediately after

See the Full Dosing Instructions on DailyMed →

Side Effects

Paclitaxel commonly causes a range of side effects because it affects both cancer cells and some healthy cells:

Common side effects

  • Low white blood cell counts (neutropenia), raising infection risk
  • Numbness, tingling, or pain in hands and feet (peripheral neuropathy)
  • Hair loss
  • Nausea and vomiting
  • Joint and muscle aches
  • Fatigue
  • Diarrhea
  • Mouth sores (mucositis)

When to get medical help

  • Signs of a severe allergic reaction: trouble breathing, sudden drop in blood pressure, swelling of the face or throat, or widespread hives — seek emergency help immediately
  • Signs of serious infection or sepsis: fever (even without low white blood cell counts), chills, or feeling very unwell — call your care team right away
  • Severe numbness, tingling, or weakness in hands or feet that gets worse — tell your doctor; dose adjustment may be needed
  • Breathing problems such as new or worsening shortness of breath or cough — may signal pneumonitis (lung inflammation)
  • Signs of bone marrow suppression: unusual bruising, bleeding, or signs of infection

Contact your care team right away if you develop a fever, have trouble breathing, notice severe or worsening numbness or weakness in your limbs, or experience signs of an allergic reaction — these can be serious and need prompt attention.

Warnings and Precautions

  • Severe bone marrow suppression (neutropenia): The most common serious risk — low white blood cell counts can lead to life-threatening infections. Blood counts must be checked regularly, and treatment may need to be paused or the dose reduced.
  • Severe allergic reactions (hypersensitivity/anaphylaxis): Can be life-threatening. Fatal reactions have occurred even with pre-medications. Anyone who has had a severe reaction must not receive paclitaxel again.
  • Severe nerve damage (sensory neuropathy): Worsening numbness or tingling may require dose reduction or treatment breaks.
  • Sepsis (bloodstream infection): Especially when albumin-bound paclitaxel is combined with gemcitabine; fever should be reported immediately.
  • Pneumonitis (lung inflammation): Has occurred with albumin-bound paclitaxel plus gemcitabine, including fatal cases; any new breathing problems should be reported right away.
  • Fetal harm: Paclitaxel can seriously harm an unborn baby. Effective contraception is required during treatment and for months after the last dose.
  • Liver impairment: Can increase paclitaxel exposure and toxicity; dose reduction may be needed and certain uses are not recommended in severe liver impairment.

Interactions

Paclitaxel is broken down by liver enzymes (CYP2C8 and CYP3A4), so medicines that affect those enzymes can change how much paclitaxel is in your body:

  • Cisplatin: Giving cisplatin before paclitaxel (rather than after) can reduce paclitaxel clearance by about one-third, increasing its effects and side effects — the order of administration matters
  • CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, saquinavir, nefazodone): May increase paclitaxel levels, raising the risk of toxicity
  • CYP3A4 inducers (e.g., rifampin, carbamazepine): May lower paclitaxel levels, potentially reducing effectiveness
  • CYP2C8 inhibitors (e.g., gemfibrozil): May increase paclitaxel exposure
  • CYP2C8 inducers (e.g., rifampin): May decrease paclitaxel exposure
  • Doxorubicin: Blood levels of doxorubicin and its active breakdown product may be higher when used alongside paclitaxel

Interactions Listed in the FDA-Approved Label

From the Paclitaxel prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Cisplatin
    What happensMyelosuppression was more profound when paclitaxel was given after cisplatin, and paclitaxel clearance decreased by approximately 33%.
    What to doGive paclitaxel before cisplatin.
  • CYP3A4 substrates, inhibitors and inducers For example: midazolam, ketoconazole, ritonavir, rifampin, carbamazepine
    What happensPaclitaxel is metabolized by CYP3A4, so these drugs may interact with it.
    What to doExercise caution when given together.
  • CYP2C8 substrates, inhibitors and inducers For example: repaglinide, rosiglitazone, gemfibrozil, rifampin
    What happensPaclitaxel is metabolized by CYP2C8, so these drugs may interact with it.
    What to doExercise caution when given together.
  • Protease inhibitors (ritonavir, saquinavir, indinavir, nelfinavir)
    What happensPotential interactions with paclitaxel have not been evaluated in clinical trials.
  • What happensPlasma levels of doxorubicin and its active metabolite doxorubicinol may be increased when used with paclitaxel.
    What to doMonitor cardiac function when used for metastatic breast cancer.
  • Polyoxyl 35 Castor Oil products For example: cyclosporin for injection concentrate, teniposide for injection concentrate
    What happensPatients with a history of severe hypersensitivity reactions to these products should not be treated with paclitaxel.
    What to doDo not treat with paclitaxel.
Read the label’s full interactions text

Drug Interactions: In a Phase I trial using escalating doses of paclitaxel (110 to 200 mg/m 2 ) and cisplatin (50 or 75 mg/m 2 ) given as sequential infusions, myelosuppression was more profound when paclitaxel was given after cisplatin than with the alternate sequence (i.e., paclitaxel before cisplatin). Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when paclitaxel was administered following cisplatin. The metabolism of paclitaxel is catalyzed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies, caution should be exercised when administering paclitaxel concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. Caution should be exercised when paclitaxel is concomitantly administered with known substrates (e.g., midazolam, buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and triazolam), inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin), and inducers (e.g., rifampin and carbamazepine) of CYP3A4. (See CLINICAL PHARMACOLOGY section.) Caution should also be exercised when paclitaxel is concomitantly administered with known substrates (e.g., repaglinide and rosiglitazone), inhibitors (e.g., gemfibrozil), and inducers (e.g., rifampin) of CYP2C8. (See CLINICAL PHARMACOLOGY. ) Potential interactions between paclitaxel, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials. Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Your neutrophil (white blood cell) count must be above a safe minimum before each treatment — paclitaxel cannot be given if counts are too low
  • Tell your doctor about any prior severe allergic reaction to paclitaxel or other taxane medicines (such as docetaxel) — this may be a contraindication
  • Tell your doctor if you have liver disease or abnormal liver tests — dose reduction or avoiding certain formulations may be necessary
  • Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding — paclitaxel can cause serious harm to a developing baby and should not be used in pregnancy; breastfeeding should be stopped during treatment and for two weeks after the last dose
  • Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose; men with female partners of reproductive potential should use contraception during treatment and for at least 3 months after the last dose
  • Safety and effectiveness in pediatric patients have not been established for approved indications
  • Older adults (65+) may experience more side effects, including bone marrow suppression, nerve effects, fatigue, diarrhea, and dehydration — closer monitoring is important
  • Mild to moderate kidney impairment does not require a starting dose adjustment; severe renal impairment has not been studied

Overdose

There is no known antidote for paclitaxel overdose. The main risks from too much paclitaxel are severe bone marrow suppression (very low blood counts), nerve damage, and mouth sores. If an overdose is suspected, emergency medical care is needed right away.

Half-Life and How Your Body Processes It

After intravenous infusion, paclitaxel (from albumin-bound formulations) distributes rapidly into tissues and is highly bound to proteins in the blood (about 94%). It is mainly broken down by liver enzymes (CYP2C8 and CYP3A4), with the half-life — the time for half the drug to clear — ranging from roughly 13 to 27 hours. Only a small amount leaves the body through the urine; most is cleared through non-kidney pathways, with about 20% exiting via the stool. Albumin-bound paclitaxel has a larger volume of distribution and faster clearance compared to standard solvent-based paclitaxel injection.

Storage

Store the vials in original cartons between 20° to 25°C (68° to 77°F). Protect from light.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Paclitaxel: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Paclitaxel — the kind of thing our pharmacy team would talk through with you at the counter.

Why is paclitaxel given as an IV infusion instead of a pill?

Paclitaxel can only be given intravenously — there's no pill form. It needs to get directly into your bloodstream to reach cancer cells throughout the body effectively. Your infusion team will handle the whole process for you in a clinic or infusion center.

I've heard there are different 'versions' of paclitaxel — does it matter which one I get?

Yes, it matters a lot. Standard paclitaxel injection and albumin-bound paclitaxel (such as Abraxane) are not interchangeable — they work differently in the body, are approved for different uses, and have different dosing schedules. Your doctor will prescribe the specific product that's right for your cancer type and treatment plan. Never switch between them without your oncologist's guidance.

What side effects should I expect, and which ones mean I need to call my doctor right away?

Very common side effects include hair loss, fatigue, nausea, joint and muscle aches, and numbness or tingling in your hands and feet. These are expected and your team can help manage them. But call your doctor immediately if you develop a fever — even a mild one — because your white blood cell count may be low and an infection could become serious quickly. Also get emergency help for any trouble breathing, throat swelling, or sudden drop in blood pressure, as these could be signs of a severe allergic reaction.

Do I need to take anything before my infusion?

If you're receiving standard paclitaxel injection, yes — you'll be given pre-medications (a steroid, an antihistamine, and an acid-reducing medicine) before each dose to lower the risk of a serious allergic reaction. Albumin-bound products like Abraxane have a different preparation process. Your infusion team will handle all of this for you, but it's good to know why it's happening.

Is it safe to try to get pregnant while on paclitaxel?

No — paclitaxel can seriously harm a developing baby. If you could become pregnant, you must use reliable birth control throughout treatment and for at least 6 months after your last dose. If you're a man, you should also use contraception to protect a partner for at least 3 months after your last dose. Talk to your doctor before treatment starts if pregnancy is something you're thinking about in the future.

Are there any medicines I should avoid while getting paclitaxel?

Yes, several medicines can interfere with how your body processes paclitaxel. Certain antifungals, antibiotics, HIV medications, and cholesterol medicines can either increase paclitaxel's effects (raising the risk of side effects) or reduce its effectiveness. Before starting treatment, tell your oncologist about every medicine, supplement, and herbal product you take so they can check for potential interactions.

Is paclitaxel available over the counter?

No. Paclitaxel is a prescription medicine: every paclitaxel product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was paclitaxel first available?

The earliest FDA record we hold for paclitaxel is from 1992: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when paclitaxel was first used.

Who makes paclitaxel?

20 companies currently list paclitaxel products in the FDA's NDC Directory, including Teva Parenteral Medicines, Inc., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of paclitaxel?

Paclitaxel is the generic name. Its brand names are Abraxane and paclitaxel Protein Bound Particles Albumin Bound. Generic versions are listed under the name paclitaxel.

What is the generic name of Abraxane?

The generic name of Abraxane is paclitaxel. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is paclitaxel?

Paclitaxel belongs to the drug class Microtubule Inhibitor, its established pharmacologic class on the FDA label.

Is there a generic version of paclitaxel?

Yes. FDA-approved generic versions of paclitaxel are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does paclitaxel come in?

Paclitaxel is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 100 mg/20 mL and 100 mg/100 mg. Injection (into a vein), amount in each mL: 6 mg/mL. A listing does not mean every pharmacy stocks every strength.

Is there a paclitaxel shortage?

No. Paclitaxel is not on the FDA's drug shortage list as of Nov 22, 2026. A single pharmacy can still run short for a while without a national shortage, and your pharmacist can tell you what they are seeing.

Where can I read the paclitaxel prescribing information (package insert)?

The full FDA-approved prescribing information for paclitaxel, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Teva Pharmaceuticals, Inc.'s, revised Nov 1, 2023, and links to it on DailyMed.

Is paclitaxel gluten free?

No paclitaxel label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 35 paclitaxel products from 18 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's paclitaxel by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See paclitaxel inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Paclitaxel

Skip the scrolling. Ask in your own words and get an answer from Paclitaxel’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Paclitaxel’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Paclitaxel on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Paclitaxel Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Paclitaxel Forms and Strengths (How It Comes)

Paclitaxel comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Paclitaxel inactive ingredients by manufacturer.

Injection

Into a vein
Brands Abraxane (2005) Paclitaxel Protein Bound Particles Albumin Bound
How this form is used
What it may be used for
  • Abraxane (and albumin-bound paclitaxel products) is used for metastatic breast cancer after prior combination chemotherapy has failed, first-line non-small cell lung cancer in combination with carboplatin, and first-line metastatic pancreatic adenocarcinoma in combination with gemcitabine
  • Paclitaxel injection (solution/concentrate) is used for advanced ovarian cancer, breast cancer after failed chemotherapy, first-line non-small cell lung cancer in combination with cisplatin, adjuvant node-positive breast cancer, and second-line AIDS-related Kaposi's sarcoma
Important instructions
  • Abraxane and albumin-bound formulations are given as an intravenous infusion on a schedule set by your oncologist; do not substitute Abraxane or albumin-bound products for other paclitaxel formulations — they are not interchangeable
  • Paclitaxel injection (solution) requires pre-medications (a steroid, antihistamine, and acid reducer) before each dose to help prevent serious allergic reactions
  • The infusion site must be closely monitored for leakage (extravasation) during and after administration
  • Paclitaxel injection solution should be stored and administered using non-PVC containers and tubing to avoid exposure to the plasticizer DEHP
Available strengths 3 strengths
39 FDA-listed product records ⓘ

Paclitaxel on the U.S. Market: Products, Makers and Brands

How Paclitaxel appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

20 companies list 39 Paclitaxel product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1992. Brand names in the directory today include Abraxane and Paclitaxel Protein Bound Particles Albumin Bound; the rest are generics.

1
Dose forms ⓘ
20
Labelers (makers, repackagers, distributors)
2
Brand names ⓘ
39
FDA-listed product records ⓘ
1992
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (19) · Unfinished injection (1) · Unfinished injection, powder, for solution (1) · Unfinished injection, powder, lyophilized, for suspension (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Teva Parenteral Medicines, Inc.10%
Alembic Pharmaceuticals Inc.8%
Alembic Pharmaceuticals Limited8%
BluePoint Laboratories8%
Gland Pharma Limited8%
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.8%
Other makers51%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Paclitaxel Is Used (Medicaid Data)

How many Paclitaxel prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

58,387
Medicaid prescriptions filled (Q1–Q4 2025)
$30.9M paid by Medicaid, before rebates

How commonly is Paclitaxel prescribed? Of the 1,682 medications we measure, Paclitaxel ranks #618 by Medicaid prescriptions — more than 63% of them.

Where Paclitaxel ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Paclitaxel product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 6 mg/mL injectable solution is the most-dispensed Paclitaxel product — about 76% of these Medicaid prescriptions.

paclitaxel 6 MG/ML Injectable Solution Most dispensed

44,452 Medicaid prescriptions (Q1–Q4 2025) 76% of Paclitaxel prescriptions shown $4.9M paid by Medicaid, before rebates ≈ $111 per prescription, before rebates

23 of 59 listed NDCs had Medicaid claims. RxNorm 312199

paclitaxel 100 MG Injection

13,935 Medicaid prescriptions (Q1–Q4 2025) 24% of Paclitaxel prescriptions shown $25.9M paid by Medicaid, before rebates ≈ $1,860 per prescription, before rebates

7 of 12 listed NDCs had Medicaid claims. RxNorm 583214

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 30 of the 71 listed Paclitaxel NDCs had Medicaid claims.

Compare Paclitaxel Products

A representative set of FDA-listed product records for Paclitaxel — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 39 of 39 products — FDA National Drug Code Directory. See every product, package size and price: browse all 39 Paclitaxel NDCs →

Paclitaxel Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Paclitaxel recalls since July 2021.

✅No Paclitaxel recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Paclitaxel in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
2
Strengths
2
Forms in current FDA listings
2 of 2
In current FDA listings No current FDA listing
Ingredient (IN) Paclitaxel RxCUI 56946
  1. Dose form (SCDF) Injectable Solution RxCUI 377111
    In current FDA listings
    Its strength (SCD)
  2. Dose form (SCDF) Injection RxCUI 1663181
    In current FDA listings
    Its strength (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Paclitaxel Brand Names

Paclitaxel has 2 brand names on record: Abraxane and Paclitaxel Protein Bound Particles Albumin Bound. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Abraxane 2005 Paclitaxel Protein Bound Particles Albumin Bound

Who Makes Paclitaxel: Manufacturers and Labelers

20 companies list Paclitaxel products with the FDA. By number of product records, the largest are Teva Parenteral Medicines, Inc., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Teva Parenteral Medicines, Inc. 4 Alembic Pharmaceuticals Inc. 3 Alembic Pharmaceuticals Limited 3 BluePoint Laboratories 3 Gland Pharma Limited 3 Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 3 Natco Pharma USA LLC 3 Novadoz Pharmaceuticals LLC 3 Hospira, Inc. 2 NorthStar Rx LLC 2 Abraxis BioScience, LLC 1 American Regent, Inc. 1 Bryant Ranch Prepack 1 Fresenius Kabi USA, LLC 1 Meitheal Pharmaceuticals Inc. 1 Mylan Institutional LLC 1 Ningbo Shuangcheng Pharmaceutical Co., Ltd 1 Sagent Pharmaceuticals 1 Sandoz Inc 1 Teva Pharmaceuticals, Inc. 1

Sources for This Paclitaxel Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Nov 1, 2023, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Paclitaxel.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 25 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
25
Finished products in the current FDA directory
39
Companies listing them (makers, repackagers, distributors)
20
FDA labeler codes behind them ⓘ
21
Linked representative label ⓘ
Teva Pharmaceuticals, Inc.
Linked label effective
Nov 1, 2023
Composite sections available
25
Linked SPL Set ID
15dd51ed-29e8-468b-b6d1-21b1f84d6f2e
Linked SPL Document ID
2fbc2699-cf99-497c-94b9-8a2c534c061f
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →